Shares of Connect Biopharma whipsawed this week, plunging 32.17% on September 15 before rebounding 10.3% to $1.29 the following session, as investors picked through the wreckage of a Phase 2 asthma trial that delivered encouraging clinical signals but failed the one test Wall Street cares about most: statistical significance on its primary endpoint. Connect Biopharma's Asthma Drug Cut Treatment Failures by 66% but Flunked Its Key Test — Can Investors Trust the Rebound?

Shares of Connect Biopharma lurched 32% lower on September 15 and then snapped back 10.3% to $1.29 the next day, as Wall Street digested a Phase 2 asthma trial that delivered genuinely promising clinical signals but stumbled on the measure that matters most for regulators. CEO Barry Quart highlighted "statistically significant rapid improvements in FEV1 within one week" alongside a "66% reduction in treatment failures at 28 days, although that endpoint did not reach statistical significance." For a company with a market cap of roughly $110 million and a fiscal 2025 net loss of $55.5 million , the distinction between "encouraging" and "statistically proven" is existential.

  • The Drug Worked, but Not Enough to Satisfy the Math. Rademikibart produced a statistically significant lung-function improvement at Day 7 — a 250 mL increase in air exhaled in one second versus 120 mL for placebo (p=0.023).

Emergency or unscheduled medical visits dropped 50% versus placebo, and no new safety concerns emerged. Yet the primary endpoint — treatment failure over 28 days — missed the statistical bar, meaning the FDA cannot treat the result as definitive proof. With only 160 patients split between drug and placebo , the trial may simply have been too small to capture a statistically significant difference, but that distinction won't comfort shareholders who watched the stock crater.

  • A Second Catalyst Looms This Month. Connect expects to report results from a separate Phase 2 trial testing the same drug in COPD patients with inflammation-driven flare-ups later in September, and plans to quickly seek FDA guidance on a larger, Phase 3 program. If the COPD data reinforce the asthma signals, the company could argue the drug's clinical profile justifies advancing — but another miss would likely be devastating at these price levels.

  • Cash Is Finite and the Clock Is Ticking. Management said its cash runway extends at least one year from August 2026.

Annual revenue was just $64,000 against a $55.5 million net loss , meaning Connect burns cash almost exclusively. A Phase 3 trial would require significant additional capital — likely through dilutive share sales — precisely when the stock is trading near its 52-week low of $1.23 .

  • Analysts Still See Upside, but the Gap Is Startling. Eight analysts maintain a consensus "Strong Buy" with an average $7.25 price target — more than 5× today's price. That gap reflects either deep conviction in the drug's billion-dollar market potential or price targets that haven't caught up to reality. The company cites roughly 1.6 million U.S. emergency visits annually for acute asthma flare-ups in the target patient population , a large addressable market — but reaching it requires clearing regulatory hurdles this trial did not.